Compass Pathways (NASDAQ:CMPS) executives outlined the company’s latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami ...

Eli Lilly and Co. LLY shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the ...

Ad hoc announcement pursuant to Art. 53 LRBASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) -- BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial ...

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, ...

China’s Yangtze Memory Technologies plans to build two fabs beyond the Phase 3 plant that it’s due to complete in Wuhan this ...

With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its ...

Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy of alixorexton compared with placebo in adults, according to a news release.

Nipocalimab demonstrates significant long-term efficacy and safety in generalized myasthenia gravis, improving MG-ADL scores and reducing immunoglobulin G levels. The phase 3 Vivacity-MG3 study ...

Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...

Hello, and welcome to this market update with the Swedish Diabetes Research Company, Diamyd Medical. On Friday evening, the company announced negative interim results from its Phase III study. We will ...

Construction for the next phase is expected to start in the spring, and they hope to have everything complete by 2028.